product quality resulting in low production costs. Subsequently, the active pharma­ceutical ingredient would be formulated in liquid form with high chemical, confor­mational, colloidal, and physical stability during shipping and storage over its shelf life and would be easily administrable at the concentrations required for effective dosing [11]. However, the real circumstances of the biopharmaceutical industry deviate substantially from this idealized state, since the majority of lead candidates experience development issues that are related to their unfavorable biophysical properties, but the specic reasons behind a drug failure in the development phase remain often poorly documented and therefore not fully understood [4]. Increasing the complexity, next-generation drugs of multi-specic mAb derivatives tend to have even greater CMC hurdles [12, 13]. Additionally, the quality target product prole dening the key design requirements of the nal drug product is not fully dened in the early development stages [14]. The therapeutic dose and regimen for clinical studies are not yet dened and need to be established in preclinical experi­ments with the same material that is used in the clinical studies [15]. The anticipated administration route might change during the development as well as the primary packaging and/or the inclusion of a medical device [16]. All these design choices bring different and additional requirements on different physicochemical properties of the biologics and the formulation that can also modify the platform manufactur­ing processes. Examples are solution viscosity, resistance to shear stress, interaction on air: water and interfaces, compatibility to a liquid or lyophilized formulation, compatible excipients, and active pharmaceutical ingredient (API) concentration. Therefore, the biopharmaceutical industry aspires to meet the increasing demand for modern biotherapeutics by improving their developability via rational design.